Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2017 07:30 ET | Source: Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Auryxia® (ferric citrate) Tablets

BOSTON, March 08, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
March 01, 2017 07:00 ET | Source: Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results

Fourth quarter and Full Year 2016 Auryxia® (ferric citrate) net U.S. product sales of $8.2 million and $27.2 million, respectively Early 2017 Auryxia prescription demand showing positive momentum and...
February 23, 2017 08:31 ET | Source: Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals to Webcast its Presentations at Two Investor Conferences in March 2017

BOSTON, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc., (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
February 16, 2017 09:15 ET | Source: Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 1, 2017

BOSTON, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease,...
February 08, 2017 09:01 ET | Source: Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals to Webcast its Presentation at RBC Capital Markets' 2017 Global Healthcare Conference on February 22, 2017

BOSTON, Mass., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease,...
January 12, 2017 09:53 ET | Source: Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals Announces Publication of Auryxia® (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology

BOSTON, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
January 08, 2017 18:00 ET | Source: Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference

Enters 2017 with positive momentum for Auryxia® (ferric citrate) in dialysis; preliminary unaudited fourth quarter net U.S. product sales of $8.2 millionSubmitted supplemental new drug application...
December 22, 2016 08:31 ET | Source: Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgan’s 35th Annual Healthcare Conference on January 11, 2017

BOSTON, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
November 18, 2016 10:31 ET | Source: Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASN’s Kidney Week

CHICAGO, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
November 17, 2016 10:31 ET | Source: Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals Announces Multiple Scientific Presentations of Phase 3 Trial Results of Ferric Citrate for Iron Deficiency Anemia (IDA) in Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)

Pivotal Phase 3 data showed the potential of Ferric Citrate (Auryxia®) to treat IDA in adults with NDD-CKD Phase 3 trial results support supplemental new drug application (sNDA) seeking to...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right